During ASCO 2020, held 29 May – 2 June, presentations in the melanoma field highlighted the efforts to reduce or optimise the use of ICIs with the intention to lessen excessive toxicities in patients. Study results suggest sometimes “less is more”, however, determining for which patient populations less treatment will be better is another question that needs to be answered.
A Phase II dose-sparing study presented by Michael A Postow, MD demonstrated that half of the recommended four-dose treatment with Opdivo + Yervoy combination could be adequate in provoking an anti-cancer immune response. Read more here.
Go deeper with GlobalData
